Digestive Health & Gastroenterology Clinical Trials Update: Week 24, 2026

Published June 12, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)

This Phase 2 study is exploring a new RNA-based treatment called ALN-CIDEB for adults with fibrotic Metabolic Dysfunction-Associated Steatohepatitis, a serious liver condition involving fat buildup and scarring. If successful, this therapy could help reduce liver fat and damage, potentially improving liver health and symptoms for those affected. The study plans to enroll 150 participants and is not yet recruiting.

Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease

This Phase 2 trial is testing the drug tirzepatide for people with Crohn's disease who experience hard-to-treat inflammation in the small bowel. The goal is to find a treatment that promotes healing beyond simply controlling inflammation, which could offer new hope for those who have not responded well to current therapies. The study is currently recruiting in the United States and involves colonoscopy and sample collection to carefully assess the treatment effects.

Patient Reminders Optimizing Mail-in Prevention Testing for Colorectal Cancer

This completed study looked at ways to encourage adults aged 45 to 75 to return stool testing kits for colorectal cancer screening. By increasing the return rates of these kits, the study aimed to make cancer screening more accessible and convenient, which could lead to earlier detection and better health outcomes. Over 2,000 participants took part in the trial in the United States, and the results will help improve future screening programs.

Endoscopic Injection of Autologous Fat-Derived Cells (SVF) for Adults With Refractory Gastroesophageal Reflux Disease (GERD). (The GERD-REVIVE Pilot Study)

This pilot study is testing a new treatment where a patient’s own fat-derived cells are injected endoscopically to treat adults with GERD that does not respond well to medication. If this approach proves safe and effective, it may offer a less invasive option to improve symptoms and reduce dependence on daily acid-reducing drugs. The study plans to enroll 15 participants and will provide early information on safety and feasibility.

The Bioavailability and Effect on Pouch pH of Esomeprazole After Gastric Bypass

This Phase 4 study is comparing esomeprazole tablets versus a solution form to see how each affects acid levels in the stomach pouch of patients who have had gastric bypass surgery. Understanding which form works better could help improve symptom management for patients dealing with obesity and gastric reflux after surgery. The trial is recruiting 50 participants in Switzerland.

This week saw a diverse range of studies in digestive health, from innovative treatments targeting liver and bowel conditions to efforts improving cancer screening and reflux management. These trials reflect ongoing efforts to find better and more personalized care options for patients facing digestive diseases. Continued research in these areas holds promise for improving quality of life and health outcomes in the near future.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.